© 2019 Peptilogics  I  All Rights Reserved

News & Updates

Peptilogics is attending the 37th Annual J.P. Morgan Healthcare Conference on January 7-10, 2019

Therapeutic Development to Address Potential Orphan Indication and Global Pandemic

Peptilogics, which develops peptide-based therapeutics with its computational  biology platform, announced today that it has been cleared by Australia’s Therapeutics Goods Administration to begin the first in-human Phase 1 study of PLG0206, which is being developed to address prosthetic joint infection (PJI) and the global pandemic of multi-drug resistant bacterial infections. The PLG0206 clinical study received ethics app...

Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of PLG0206 for the treatment of prosthetic joint infections (PJI). PJI is one of the most challenging complications of joint arthroplasty and a serious, life-threatening condition with few...

June 26, 2018

The AMR Industry Alliance features case studies to provide snap-shots from across the life-sciences industry, share information on the tangible steps taken to invest in new research to develop new antibiotics and vaccines, prevent infection ,and improve appropriate use of antibiotics.

Additional details can be found here.

Health needs

Prosthetic Joint Infection (PJI) is one of the most challenging complications of joint arthroplasty and a serious, life threatening condition with few effective treatment opt...

Builds on PLG0206 studies published in Nature Scientific Reports. 
Company to present at BIO in Boston on June 5.

Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced that its lead compound PLG0206 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for the treatment of prosthetic joint infections (PJI).

PJI is one of the most challenging complicati...

January 19, 2018

  • The new AMR Industry Alliance of more than 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations launches its first progress report today. The report measures action taken in four areas: research and science, access, appropriate use, and the environment.

  • In 2016, the report shows that 22 Alliance companies invested at least USD 2 billion in R&D dedicated to AMR-related products. The funds cover costs for early-stage R&D, exploring new product c...

Thiel joins leading investors Stefan Roever and BlueTree Ventures in Series A round Company appoints Sanjay Kakkar as Chief Executive Officer

Peptilogics, a pre-clinical stage company utilizing an innovative peptide platform to treat multidrug-resistant bacterial infections, announced today that it closed a $5.5 million Series A financing with participation from Peter Thiel, Stefan Roever, BlueTree Ventures and others. Peptilogics, founded by Jonathan Steckbeck, who serves as President and Chief Scientif...

Please reload